<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098599</article-id><article-id pub-id-type="publisher-id">1503961</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1503961</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Sanqi oral solution alleviates podocyte apoptosis in experimental membranous nephropathy by mediating EMT through the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway</article-title><alt-title alt-title-type="left-running-head">Wang et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xlink:href="https://doi.org/10.3389/fphar.2025.1503961" ext-link-type="uri">10.3389/fphar.2025.1503961</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Xiaowan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Juanjuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1579263/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Bidan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1677242/overview"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Ruimin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Lihua</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1556012/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Feng</surname><given-names>Yi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Bo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/464510/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xu</surname><given-names>Peng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/563031/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x00026; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>State Key Laboratory of Dampness Syndrome of Chinese Medicine</institution>, <institution>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Nephrology</institution>, <institution>Guangdong Provincial Hospital of Chinese Medicine</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Guangdong Provincial Academy of Chinese Medical Sciences</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/483551/overview" ext-link-type="uri">Alessandra Durazzo</ext-link>, Council for Agricultural Research and Economics, Italy</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xlink:href="https://loop.frontiersin.org/people/88841/overview" ext-link-type="uri">Ahmed Esmat Abdel Moneim</ext-link>, Helwan University, Egypt</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/3013333/overview" ext-link-type="uri">Sudipta Ghorai</ext-link>, Vidyasagar University, India</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/3014451/overview" ext-link-type="uri">Jun Liu</ext-link>, North Sichuan Medical College, China</p><p>
<ext-link xlink:href="https://loop.frontiersin.org/people/3024038/overview" ext-link-type="uri">Xiandeng Li</ext-link>, Chongqing Medical University, China</p></fn><corresp id="c001">*Correspondence: Peng Xu, <email>xupeng@gzucm.edu.cn</email>; Bo Liu, <email>doctliu@gzucm.edu.cn</email>; Yi Feng, <email>fy1633@126.com</email>
</corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#x02020;</sup>
</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1503961</elocation-id><history><date date-type="received"><day>30</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Wang, Wang, Zheng, Tian, Huang, Mao, Feng, Liu and Xu.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Wang, Zheng, Tian, Huang, Mao, Feng, Liu and Xu</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Sanqi oral solution (SQ) is a Chinese medicine that has been used well to treat idiopathic membranous nephropathy (IMN). It has been demonstrated to mitigate IMN proteinuria by inhibiting podocyte apoptosis. however, the precise mechanism has not been fully elucidated.</p></sec><sec><title>Methods</title><p>A passive Heymann nephropathy (PHN) rat model was used to mimic the <italic>in vivo</italic> disease characteristics of IMN. The PHN rats were intragastrically administered SQ (12.6/6.3&#x000a0;mL/kg) or tacrolimus (0.315&#x000a0;mg/kg) for 21&#x000a0;days. SQ was applied to ADR-induced podocytes <italic>in vitro</italic>. The effects of SQ on IMN and its underlying mechanisms were determined by measuring biochemical indices, pathomorphological characteristics, membrane attack complex (MAC), cell morphology, and protein levels.</p></sec><sec><title>Results</title><p>The SQ ingredients found in rat serum underscored their successful absorption in rats. In PHN rats, SQ induced a significant reduction in proteinuria, MAC, C5b-9, and glomerular basement membrane thickness, along with a drop in apoptotic podocytes. Similarly, SQ exerted a protective effect against ADR-induced podocyte injury by inhibiting apoptosis. Furthermore, inhibition of the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway-mediated epithelial-to-mesenchymal transition (EMT) was found to be involved in the anti-apoptotic effect of SQ in PHN rats and podocytes, marked by the reduction in vimentin and &#x003b1;-SMA and the induction of Synaptopodin and Podocin protein levels.</p></sec><sec><title>Conclusion</title><p>Inhibition of EMT via the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway may be the main mechanism by which SQ suppresses podocyte apoptosis in IMN.</p></sec></abstract><kwd-group><kwd>passive heymann nephropathy</kwd><kwd>sanqi oral solution</kwd><kwd>apoptosis</kwd><kwd>epithelialmesenchymal transition</kwd><kwd>the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Natural Science Foundation of China (No. 82305132), Science and Technology Projects of Guangzhou (Nos. 202201020487, 202201020556, and 202201020488), the Specific Fund of State Key Laboratory of Dampness Syndrome of Chinese Medicine (Nos. SZ2023ZZ05, SZ2021ZZ11 and SZ2021ZZ24), the Science and Technology Projects of Guangdong Provincial Hospital of Chinese Medicine (No. YN2024HK08), the Research Fund for Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine (Nos. BJ2022KY16 and BJ2022KY08), Natural Science Foundation of Guangdong Province (No. 2022A1515010103), and Special Project for International Cooperation in Traditional Chinese Medicine of the National Administration of Traditional Chinese Medicine (Nos. 0610-2240NF021549 and 0610-2240NF021548).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Ethnopharmacology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Highlights</title><p>
<list list-type="simple"><list-item><p>1. The main active ingredients of SQ could be absorbed by rats, which underlay the effectiveness of SQ.</p></list-item><list-item><p>2. The ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway was required for EMT in apoptosis podocytes.</p></list-item><list-item><p>3. SQ could reduce apoptotic podocytes in IMN by inhibiting EMT via the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway.</p></list-item></list>
</p></sec><sec sec-type="intro" id="s2"><title>1 Introduction</title><p>Idiopathic membranous nephropathy (IMN) is a pathomorphologically defined proteinuric glomerular disease and a common cause of adult nephrotic syndrome (<xref rid="B32" ref-type="bibr">Morelle et al., 2025</xref>). IMN is typically characterized by a distinct thickening of the glomerular capillary walls resulting from the subepithelial embedding of immune deposits in the glomerular basement membrane (GBM), together with podocyte foot process detachment (<xref rid="B19" ref-type="bibr">Kistler and Salant, 2024</xref>). Immune deposits activate the complement cascade to produce assembled C5b-9 in the course of IMN, and podocytes are a major target in this process (<xref rid="B29" ref-type="bibr">Liu Z. et al., 2025</xref>). Podocytes are important barriers to maintain glomerular filtration function and are vulnerable to injury in IMN (<xref rid="B59" ref-type="bibr">Zhang et al., 2024</xref>). Injured podocytes detach from the GBM, inducing proteinuria (<xref rid="B1" ref-type="bibr">Cai et al., 2024</xref>). As specialized, highly differentiated terminal cells, podocytes will die after being injured by C5b-9 (<xref rid="B14" ref-type="bibr">Jiang et al., 2023</xref>). Apoptosis is the main type of podocyte death and directly associated with the degree of proteinuria and renal hypofunction (<xref rid="B27" ref-type="bibr">Liu et al., 2023</xref>; <xref rid="B43" ref-type="bibr">Wang et al., 2023</xref>). Therefore, preventing podocyte injury is of importance to relieve proteinuria and inhibit IMN progression.</p><p>How nociceptive stimuli lead to podocyte injury and apoptosis in the IMN remains debatable. In recent years, research on podocyte injury has focused on the epithelial-to-mesenchymal transition (EMT) process (<xref rid="B23" ref-type="bibr">Li et al., 2022</xref>; <xref rid="B5" ref-type="bibr">Dan Hu et al., 2023</xref>; <xref rid="B58" ref-type="bibr">Yue et al., 2024</xref>). During EMT, podocytes undergo a phenotypic transformation from epithelial cells to mesenchymal cells following stimulation, characterized by loss of epithelioid marker proteins such as Nephrin, Podocin, and Synaptopodin, while acquiring mesenchymal characteristics such as increased vimentin and &#x003b1;-SMA expression (<xref rid="B63" ref-type="bibr">Zheng T. et al., 2025</xref>). EMT will cause podocyte motion and affects adhesion to the GBM, resulting in the loss of podocyte integrity, fusion of podocytes, disappearance of the hiatal septum, and podocyte apoptosis (<xref rid="B10" ref-type="bibr">Huang et al., 2025</xref>). Therefore, podocyte EMT plays a vital role in the destruction of the glomerular filtration barrier.</p><p>Numerous studies have shown that traditional Chinese medicine has distinctive benefits in treating glomerular disease (<xref rid="B31" ref-type="bibr">Miao et al., 2022</xref>; <xref rid="B47" ref-type="bibr">Wang et al., 2024</xref>; <xref rid="B24" ref-type="bibr">Li et al., 2025</xref>; <xref rid="B48" ref-type="bibr">Wang et al., 2025</xref>). Sanqi oral solution (SQ) is a classic traditional Chinese medicine developed by the famous doctor Nizhi Yang from Guangdong Province, China. It is composed of Panax notoginseng (Burkill) F.H. Chen (Sanqi), and Astragalus mongholicus Bunge (Huangqi). SQ has been used to treat chronic kidney disease (CKD) for several years and good therapeutic efficiency has been chieved (<xref rid="B4" ref-type="bibr">Dai et al., 2013</xref>). Research has demonstrated that SQ or Sanqi-Huangqi herb-pair exerted renal protective effect in CKD via inhibiting macrophage inflammatory response (<xref rid="B49" ref-type="bibr">Wei et al., 2013</xref>; <xref rid="B40" ref-type="bibr">Tan et al., 2020</xref>). It was also confirmed that SQ reduces renal injury in diabetic nephropathy by inhibiting the inflammatory response of infiltrated macrophages and upregulating autophagy (<xref rid="B50" ref-type="bibr">Wen et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Lin et al., 2022</xref>). According to traditional Chinese medicine, SQ has the function of promoting blood circulation and invigorating Qi in CKD, including diabetic nephropathy. Our previous study has shown that SQ could alleviate fatigue in rats with Qi deficiency and blood stasis induced by exhaustive swimming (<xref rid="B52" ref-type="bibr">Xu et al., 2019</xref>). As a type of CKD, IMN can also be attributed to Qi deficiency and blood stasis; hence, Chinese physicians have recommended to treat IMN with herbs that invigorate Qi and promote blood circulation (<xref rid="B21" ref-type="bibr">Lang et al., 2020</xref>). SQ has been used to treat IMN for many years, and SQ could effectively mitigate proteinuria and slow down IMN progression. We also found that SQ inhibited podocyte apoptosis in rats with passive Heymann nephropathy (PHN) and inhibited IMN progression (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>). However, the underlying mechanism has not yet been fully elucidated.</p><p>In the present study, ERK was identified as a key protein that regulates the EMT. The influence of SQ on podocyte apoptosis via ERK-mediated EMT was also expored in IMN <italic>in vivo</italic> and <italic>in vitro</italic>.</p></sec><sec sec-type="materials|methods" id="s3"><title>2 Materials and methods</title><sec id="s3-1"><title>2.1 Analysis of SQ ingredients in rat serum using UPLC-QQQ-MS/MS</title><p>SQ ingredients in rat serum were detected using UPLC-QQQ-MS/MS with high sensitivity and specificity. Reference standard for caylcosin-7-O-&#x003b2;-D-glucopyranoside, notoginsenoside R1, puerarin, and saikosaponin a were purchased from the China National Institute for the Control of Pharmaceutical and Biological Products (purity 98%; Beijing, China). The reference standards for ginsenosides Rb1, Rd, Re, Rg1, calycosin, and ononin were obtained from PUSH BIO-TECHNOLOGY (Chengdu, China). UPLC-QQQ-MS/MS was performed using Shimadzu LC-30A (Shimadzu Corporation, Kyoto, Japan) and SCIEX Triple QuadTM 6500 (AB Sciex Pte. Ltd, California, United States) coupled with a mass spectroscopy system equipped with an Acquity UPLC BEH C18 column (1.7 &#x000b5;m, 100 &#x000d7; 2.1&#x000a0;mm). The mobile phase consisted of 5&#x000a0;mM ammonium acetate aqueous solution (A) and acetonitrile (B) in the gradient mode. The injection volume for each sample was 3&#x000a0;&#x003bc;L. The preparation method for the SQ-treated rat serum samples and detailed protocols are provided in the <xref rid="s13" ref-type="sec">Supplementary Material</xref>.</p></sec><sec id="s3-2"><title>2.2 Preparation of SQ</title><p>SQ (Batch No. 210102; Cantonese Medicine Ratification No. Z20071155), extracted from Astragalus mongholicus Bunge (0.333&#x000a0;g/mL) and Panax notoginseng (Burkill) F.H. Chen (0.056&#x000a0;g/mL), was provided and authenticated by Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China). The botanical entities of Astragalus mongholicus Bunge and Panax notoginseng (Burkill) F.H. Chen can be identified at <ext-link xlink:href="https://mpns.science.kew.org/mpns-portal/" ext-link-type="uri">https://mpns.science.kew.org/mpns-portal/</ext-link>. SQ was obtained via water extraction and alcohol precipitation. The main components of SQ were analyzed using high-performance liquid chromatography coupled with ultraviolet spectroscopy, as described in our previously published study (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>). The lyophilized powder of Sanqi oral solution (SQL) was prepared as described in our previously published study (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>). Briefly, SQ solutions were frozen in 100&#x000a0;mm culture dishes at &#x02212;80&#x000b0;C for 48&#x000a0;h and dried under vacuum conditions at &#x02212;60&#x000b0;C to &#x02212;70&#x000b0;C to obtain SQL. SQL was stored at &#x02212;80&#x000b0;C until use. The components and characteristic chromatograms of the SQ are shown in <xref rid="s13" ref-type="sec">Supplementary Table S1</xref> and <xref rid="s13" ref-type="sec">Supplementary Figure S1</xref>.</p></sec><sec id="s3-3"><title>2.3 Animals and ethics statement</title><p>Specific pathogen-free (SPF) male Sprague-Dawley (SD) rats were used in this study. Rats were purchased from the Medical Experimental Animal Center of Guangdong Province (Production Certification No. SCXK 2019-0035, Guangzhou), and maintained at the Experimental Animal Center of Guangdong Provincial Hospital of Chinese Medicine (Use Certification No. SYXK 2018-0094, Guangzhou). All rats were acclimatized for 3&#x000a0;days before the experiment and housed under standard conditions at a constant temperature (20&#x000b0;C &#x000b1; 2&#x000b0;C), humidity (50% &#x000b1; 10% humidity), and artificial lighting from 07:00 to 19:00. The rats had free access to standard laboratory food and water. All animal experiments were conducted in accordance with the guidelines of the International Association for Assessment and Accreditation of Laboratory Animal Care and were approved by the Animal Care and Use Committee of Guangdong Provincial Hospital of Chinese Medicine (Ethics approval No. 2021079).</p></sec><sec id="s3-4"><title>2.4 PHN establishment and experimental design</title><p>The PHN model was established in rats weighing 180&#x02013;220&#x000a0;g using a single caudal vein injection of anti-Fx1A antiserum (#PTX-002S; PROBETEX, San Antonio, CA, USA) in accordance with reagent instruction and published studies (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>; <xref rid="B61" ref-type="bibr">Zhao et al., 2024</xref>). Thirty rats were randomly divided into five groups (n = 6 rats per group): (1) control group (CON), (2) PHN group (PHN), (3) SQ low-dose group (SQ-L), (4) SQ high-dose group (SQ-H), (5) the tacrolimus group (TAC, Batch No. 22009252, Cantonese medicine ratification No. H20083039). For animal experiment, we used equivalent doses that were one and two times the clinical dose of SQ, 6.3&#x000a0;mL/kg and 12.6&#x000a0;mL/kg, respectively. TAC was employed as the positive control (<xref rid="B7" ref-type="bibr">Fern&#x000e1;ndez-Ju&#x000e1;rez et al., 2021</xref>), and its dosage was determined based on clinical dosage using the rat-human conversion coefficient (6.3). Rats in the PHN, SQ-L, SQ-H and TAC groups were given anti-Fx1A antiserum (0.5&#x000a0;mL/100g) to induce proteinuria. Rats of the SQ-L, SQ-H and TAC groups were administrated with SQ (6.3 or 12.6&#x000a0;mL/kg) or TAC (0.315&#x000a0;mg/kg) by gavage once a day in the morning for 21 days, beginning on the day of modeling. During model establishment or treatment, the rats in the CON and PHN groups received water. Throughout the experiment, rats were weighed weekly and the doses of SQ and TAC were adjusted accordingly. At the end of the experiment, the rats were euthanized by intraperitoneal injection of pentobarbital sodium (100&#x000a0;mg/kg) and blood and renal tissues were collected.</p></sec><sec id="s3-5"><title>2.5 Biochemical parameters</title><p>To determine the protein levels in the urine, 24&#x000a0;h urine of rats was collected and centrifuged. Blood samples were obtained and centrifuged to obtain serum, which was stored at &#x02212;80&#x000b0;C until analysis. Albuminuria and serum albumin (ALB), total cholesterol (TG), triglyceride (TC), and low-density lipoprotein cholesterol (LDL-c) levels were measured using an automatic biochemical analyzer in the clinical laboratory of Guangdong Provincial Hospital of Chinese Medicine (Guangzhou, China).</p></sec><sec id="s3-6"><title>2.6 Histological analysis</title><p>The abdominal aorta was perfused with PBS to clear blood, and the kidneys of the rats were harvested. Renal specimens were fixed in 4% (w/v) paraformaldehyde, embedded in paraffin, and cut into 3-&#x000b5;m sections, which were stained with hematoxylin and eosin (H&#x00026;E). General morphology was examined using a light microscope (Olympus BX53, Japan).</p></sec><sec id="s3-7"><title>2.7 Transmission electron microscopy</title><p>The electron density in the kidneys was examined by transmission electron microscopy, as described in our previously published article (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>). In brief, cubes of the renal cortex (1&#x000a0;mm<sup>3</sup>) were fixed in 5% glutaraldehyde for 2&#x000a0;h and immersed in 1% osmic acid for 1.five to two&#x000a0;h. After dehydration with gradient alcohol and immersion in the embedding solution overnight, cubes were dried and cut into 50&#x02013;70&#x000a0;nm slices, which were stained with uranyl acetate and lead citrate, and then scanned using a transmission electron microscope (JEM1400 PLUS, Japan).</p></sec><sec id="s3-8"><title>2.8 Periodic acid-silver methenamine staining</title><p>A periodic acid-silver methenamine (PASM) staining kit (Solarbio, G1790) was used to visualize the basement membrane thickness of GBM. Briefly, paraffin sections were dewaxed in xylene and rehydrated in alcohol, followed by incubation in oxidant for 15&#x000a0;min, staining with Ammonium Ferric Sulfate Solution for 10 min, and staining with Methenamine Silver Working Solution at 60&#x000b0;C for 20&#x02013;30&#x000a0;min until the sections turned black. The sections were soaked in Hypo Solution for 1&#x000a0;min, stained with Gold Chloride Solution for 1&#x000a0;min, and re-dyed with a Light Green Solution for 1&#x000a0;min. Finally, the stained sections were dehydrated using an alcohol gradient, transparentized in xylene, and sealed with neutral gum. All the sections were viewed under a light microscope (Olympus BX53, Japan). The mean density of black metal gold was measured in five randomly captured fields of six sections using Image Pro Plus (Bio-Rad Laboratories, Hercules, CA, United States).</p></sec><sec id="s3-9"><title>2.9 Hoechst 33342 staining</title><p>Apoptotic cells in the renal cryosections from each group were visualized using Hoechst 33342 staining (Boster, AR0039) at room temperature for 5&#x000a0;min. The stained renal cryosections were washed with TBST solution and examined under a fluorescence microscope (Nikon Eclipse E800).</p></sec><sec id="s3-10"><title>2.10 Cell culture</title><p>The conditionally immortalized temperature-sensitive mouse podocyte cell line was a gift from Professor Peter Mundel (Medical College, Harvard University, Boston, MA, United States). Podocytes were induced to proliferate in RPMI 1640 culture medium containing 10% fetal bovine serum and 10 U/mL recombinant IFN-&#x003b3; (Sigma, St. Louis, MO, United States) at 33&#x000b0;C. Podocytes were induced to differentiate at 37&#x000b0;C in the absence of interferon-&#x003b3; for 10&#x02013;14&#x000a0;days. SQL was dissolved in PBS and stored at &#x02212;20&#x000b0;C. Differentiated podocytes were cultured overnight at 37&#x000b0;C and treated with 400&#x000a0;ng/mL ADR, with or without 600&#x000a0;&#x003bc;g/mL SQL, for 24&#x000a0;h. ADR and SQL concentrations were chosen based on our previous study (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>).</p></sec><sec id="s3-11"><title>2.11 Immunofluorescence and cytoskeleton staining</title><p>OCT compound-embedded renal tissues were used for the immunofluorescence analysis of C5b-9 and Nephrin. Frozen sections (5&#x000a0;&#x000b5;m) were fixed with acetone, blocked with 5% bovine serum albumin (BSA), and stained with anti-C5b-9, anti-synaptopodin, and anti-vimentin antibodies overnight at 4&#x000b0;C, followed by incubation with Goat Anti-Mouse IgG H&#x00026;L (Alexa Fluor<sup>&#x000ae;</sup> 488) and Goat Anti-Rabbit IgG H&#x00026;L (Alexa Fluor<sup>&#x000ae;</sup> 594). The sections were observed under a fluorescence microscope (Olympus BX50). Fluorescence intensity was semi-quantitatively analyzed in five randomly selected fields of six slices using ImageJ software (Bio-Rad Laboratories, Hercules, CA, United States).</p><p>Cellular localization and expression of vimentin and &#x003b1;-SMA were examined in podocytes fixed with paraformaldehyde (w/v). After incubation with 5% bovine serum albumin (BSA) at 37&#x000b0;C for 30&#x000a0;min in the dark, podocytes were incubated with anti-vimentin or anti-&#x003b1;-SMA at 4&#x000b0;C overnight. After washing, podocytes were incubated with Goat Anti-Rabbit IgG H&#x00026;L (Alexa Fluor<sup>&#x000ae;</sup> 594) for 1&#x000a0;h and stained with DAPI for 5&#x000a0;min. To perform TUNEL staining, the ADR-induced podocyte treated with or without SQL were fixed with 4% paraformaldehyde (w/v) and incubated for 5&#x000a0;min at room temperature in PBS containing 0.3% Triton X-100. The One-step TUNEL Cell Apoptosis Detection Kit (Beyotime, C1089) was employed to evaluate apoptosis. For cytoskeletal staining, podocytes were fixed with 4% (w/v) paraformaldehyde for 5&#x000a0;min, incubated with 0.2% Triton X-100 for 10&#x000a0;min, and stained with 5&#x000a0;&#x003bc;g/mL phalloidin-iFluor 488 reagent (Cytoskeleton, Abcam) for 20&#x000a0;min in the dark. After washing, podocytes were stained with DAPI for 5&#x000a0;min. Finally, stained podocytes were washed with PBS and examined under a fluorescence microscope (Olympus BX50). Two to Five fields from three independent experiments were randomly selected for analysis, and the fluorescence intensity was measured using ImageJ software (Bio-Rad Laboratories, Hercules, CA, United States). Details of the antibodies are presented in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p>Ingredient sources and retention times.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">Ingredient</th><th align="center" rowspan="1" colspan="1">Source</th><th align="center" rowspan="1" colspan="1">MW</th><th align="center" rowspan="1" colspan="1">MRM ion pair</th><th align="center" rowspan="1" colspan="1">Retention time (min)</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">caylcosin-7-O-&#x003b2;-D-glucopyranoside</td><td align="center" rowspan="1" colspan="1">Radix Astragali</td><td align="center" rowspan="1" colspan="1">446.41</td><td align="center" rowspan="1" colspan="1">m/z 447.3&#x02192;285.1*</td><td align="center" rowspan="1" colspan="1">3.13</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">notoginsenoside R1</td><td align="center" rowspan="1" colspan="1">Radix Notoginseng</td><td align="center" rowspan="1" colspan="1">933.14</td><td align="center" rowspan="1" colspan="1">m/z 931.6&#x02192;637.5#</td><td align="center" rowspan="1" colspan="1">3.44</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">ginsenoside Re</td><td align="center" rowspan="1" colspan="1">Radix Notoginseng</td><td align="center" rowspan="1" colspan="1">947.15</td><td align="center" rowspan="1" colspan="1">m/z 945.3&#x02192;637.4#</td><td align="center" rowspan="1" colspan="1">3.52</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">ginsenoside Rg1</td><td align="center" rowspan="1" colspan="1">Radix Notoginseng</td><td align="center" rowspan="1" colspan="1">801.01</td><td align="center" rowspan="1" colspan="1">m/z 799.5&#x02192;637.5#</td><td align="center" rowspan="1" colspan="1">3.54</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">ononin</td><td align="center" rowspan="1" colspan="1">Radix Astragali</td><td align="center" rowspan="1" colspan="1">430.40</td><td align="center" rowspan="1" colspan="1">m/z 431.0&#x02192;269.1*</td><td align="center" rowspan="1" colspan="1">3.73</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">calycosin</td><td align="center" rowspan="1" colspan="1">Radix Astragali</td><td align="center" rowspan="1" colspan="1">284.26</td><td align="center" rowspan="1" colspan="1">m/z 283.0&#x02192;268.1#</td><td align="center" rowspan="1" colspan="1">3.92</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">ginsenoside Rb1</td><td align="center" rowspan="1" colspan="1">Radix Notoginseng</td><td align="center" rowspan="1" colspan="1">1109.3</td><td align="center" rowspan="1" colspan="1">m/z 1107.6&#x02192;945.6#</td><td align="center" rowspan="1" colspan="1">3.95</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">ginsenoside Rd</td><td align="center" rowspan="1" colspan="1">Radix Notoginseng</td><td align="center" rowspan="1" colspan="1">947.15</td><td align="center" rowspan="1" colspan="1">m/z 945.3 &#x02192;621.5#</td><td align="center" rowspan="1" colspan="1">4.15</td></tr></tbody></table><table-wrap-foot><fn><p>*Positive; # Negative.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-12"><title>2.12 Western blot</title><p>Total protein was extracted from renal tissues and podocytes using a tissue Protein Extraction buffer (Thermo Fisher Scientific, Rockford, IL, United States) or RIPA Lysis buffer (Beyotime, Shanghai, China) with proteinase and phosphatase inhibitor tablets (Roche, Mannheim, Germany). The total protein concentration was determined using a BCA assay kit. Next, 5 &#x000d7; Loading Buffer (CWBIO, Beijing, China) was added to the lysates, which were then incubated for 10&#x000a0;min at 100&#x000b0;C. Proteins (Loading volume: 5&#x000a0;&#x003bc;L) were separated by 10%&#x02013;12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes, which were blocked and incubated overnight with the following primary antibodies: anti-Caspase-3, anti-Bax, anti-Bcl-2, anti-vimentin, anti-&#x003b1;-SMA, anti-ERK, anti-p-ERK, anti-CK2-&#x003b1;, anti-&#x003b2;-catenin, and anti-GAPDH. The membranes were then washed, incubated with anti-rabbit or anti-mouse IgG, and washed again. Protein bands were visualized using an enhanced chemiluminescence detection system (Bio-Rad, Laboratories, Hercules, CA, United States) and signal intensities were quantified by Image Lab software 5.2.1 (Bio-Rad, Laboratories, Hercules, CA, United States).</p></sec><sec id="s3-13"><title>2.13 Statistical analysis</title><p>Statistical comparisons were conducted using SPSS software version 19.0. Multiple sets of independent quantitative data that follow a normal distribution are compared for mean using one-way ANOVA. If the one-way ANOVA is statistically significant, pairwise comparisons of mean values between groups are conducted. When the variances are equal, the least significant difference t-test (LSD-t test) is used to compare and analyze the differences in mean values between groups; when the variance is uneven, statistical analysis is performed using Dunnett&#x02019;s T3. Results are expressed as the mean &#x000b1; standard&#x02009;deviation (SD). Differences were considered statistically significant at <italic>p</italic> &#x0003c; 0.05, and differences were considered statistically significant at <italic>p</italic> &#x0003c; 0.01.</p></sec></sec><sec sec-type="results" id="s4"><title>3 Results</title><sec id="s4-1"><title>3.1 The main active ingredients in SQ are absorbed by rats</title><p>In our previously published study, the main active ingredients in commercialized SQ prepared by the water extraction alcohol precipitation method according to the Chinese Pharmacopoeia were determined (<xref rid="B42" ref-type="bibr">Tian et al., 2020</xref>), and these ingredients were set as the standard for commercialized SQ quality control. In this study, the main absorbed ingredients of SQ in rat serum were identified using UPLC-QQQ-MS/MS with high sensitivity and specificity. Positive and negative ion switching - multi-reaction monitoring (MRM) chromatograms were obtained using two mobile phase systems (5&#x000a0;mM ammonium acetate aqueous solution and acetonitrile) with gradient elution. All the ingredients were separated within 5&#x000a0;min under optimized chromatography and mass spectrometry conditions. The representative MRM chromatogram of SQ-treated rat serum is shown in <xref rid="F1" ref-type="fig">Figure 1A</xref>, and the MRM chromatogram of blank rat serum-containing standards is shown in <xref rid="F1" ref-type="fig">Figure 1B</xref>. Eight ingredients (caylcosin-7-O-&#x003b2;-D-glucopyranoside, notoginsenoside R1, ginsenoside Re, ginsenoside Rg1, ginsenoside Rb1, calycosin, ginsenoside Rd, and ononin) of SQ, assigned to Radix Astragali and Radix Notoginseng, were identified based on their retention times and MRM ion pairs (<xref rid="T1" ref-type="table">Table 1</xref>). These data indicated that the main active ingredients of SQ could be absorbed into rat blood and were a potential pharmacological basis for SQ efficacy.</p><fig position="float" id="F1"><label>FIGURE 1</label><caption><p>The main active ingredients of SQ were absorbed by rats. <bold>(A, B)</bold> MRM chromatograms of the main active ingredients of SQ in SQ-treated rat serum and blank rat serum-containing standards. (1) caylcosin-7-O-&#x003b2;-D-glucopyranoside, (2) notoginsenoside R1, (3) ginsenoside Re, (4) ginsenoside Rg1, (5) ononin, (6) calycosin, (7) ginsenoside Rb1, and (8) ginsenoside Rd.</p></caption><graphic xlink:href="fphar-16-1503961-g001" position="float"/></fig></sec><sec id="s4-2"><title>3.2 SQ relieved albuminuria and hyperlipidemia in PHN rats</title><p>
<xref rid="F2" ref-type="fig">Figure 2A</xref> shows the procedure for performing animal experiments. Albuminuria and hyperlipidemia, which are typical manifestations of IMN, were examined in all rats. The urinary protein/creatinine ratio and 24-h proteinuria in PHN rats markedly increased (<xref rid="F2" ref-type="fig">Figures 2B, C</xref>). However, treatment with SQ-L, SQ-H, and TAC inhibited the elevation of these indicators. The anti-proteinuria effect of the SQ-H was superior to that of the SQ-L. Consistent with proteinuria, serum albumin levels were lower in PHN rats than in healthy rats, and higher in SQ-H rats than in PHN rats (<xref rid="F2" ref-type="fig">Figure 2D</xref>). Similarly, PHN rats had high serum TG, TC, and LDL-c levels, and the therapeutic effect of SQ-H on the serum levels of TG, TC, and LDL-c was significant (<xref rid="F2" ref-type="fig">Figures 2E&#x02013;G</xref>). SQ-L only exerted therapeutic effects on serum TC and LDL-c levels, whereas TAC had no significant effect on lipid metabolism biomarkers. Thus, SQ could efficiently relieve albuminuria and hyperlipidemia in PHN rats in a dose-dependent manner.</p><fig position="float" id="F2"><label>FIGURE 2</label><caption><p>SQ relieved albuminuria, hyperlipidemia, and glomerular histopathological injury in PHN rats. <bold>(A)</bold> Diagram of the animal experiments. <bold>(B, C)</bold> Proteinuria was detected in rats from all groups, and the urinary protein/creatinine ratio and 24&#x000a0;h proteinuria were calculated (n = 6). <bold>(D&#x02013;G)</bold> Serum albumin, TG, TC, and LDL-c levels were measured in the peripheral blood of rats in all the groups (n = 6). <bold>(H)</bold> HE staining (magnification &#x000d7;200) and Transmission Electron Microscopy (magnification &#x000d7;30000) showed overall histomorphological changes and microscopic electron dense deposits in the kidneys of all groups, and PASM staining (magnification &#x000d7;1000) indicated the thickness of GBM in the glomeruli of all groups (n = 6). <bold>(I)</bold> The thickness of the GBM was semi-quantified (n = 6). Data are presented as the mean &#x000b1; SD from independent groups. *<italic>p</italic> &#x0003c; 0.05 vs. the CON group. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. #<italic>p</italic> &#x0003c; 0.05 vs. the PHN group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g002" position="float"/></fig></sec><sec id="s4-3"><title>3.3 SQ reduced glomerular histopathological injury in PHN rats</title><p>The typical pathological characteristics of IMN are obvious at the subcellular level, including subepithelial glomerular immune complex (electron dense) deposition and thickening of the GBM, whereas it is difficult to detect histological glomerular changes at the cellular level (H&#x00026;E staining). As shown in <xref rid="F2" ref-type="fig">Figure 2E</xref>, H&#x00026;E staining did not reveal any obvious differences in the glomerular morphology. Transmission electron microscopy images showed large amounts of subepithelial glomerular electron-dense deposits in PHN rats compared to healthy rats, and treatment with SQ and TAC significantly alleviated the pathology of PHN rats (<xref rid="F2" ref-type="fig">Figure 2H</xref>). Similarly, PASM staining indicated that PHN rats had a thicker GBM than healthy rats, whereas a thinner GMB was observed in SQ- and TAC-treated PHN rats (<xref rid="F2" ref-type="fig">Figures 2H, I</xref>). The mitigating effect of the SQ-H was better than that of the SQ-L. These results indicated that SQ significantly reduced glomerular histopathological injury in PHN rats in a dose-dependent manner.</p></sec><sec id="s4-4"><title>3.4 SQ decreased glomerular apoptotic podocytes in PHN rats</title><p>The immune complex activates the local complement system in the glomeruli to produce C5b-9, which targets podocytes to exert cellular destructive effects and is a classic type of cell death in IMN. As shown in <xref rid="F3" ref-type="fig">Figures 3A, B</xref>, deposition of C5b-9 deposition was visible in the glomeruli of PHN rats after immunofluorescence staining, and SQ decreased the expression of C5b-9 in PHN rats in a dose-dependent manner. Moreover, an increase in apoptotic podocytes was observed in PHN rats, SQ-H effectively reduced apoptosis in PHN rats (<xref rid="F3" ref-type="fig">Figure 3A</xref>). However, the antiapoptotic effects of SQL were not evident. Therefore, the SQ-H was selected to study the underlying mechanism.</p><fig position="float" id="F3"><label>FIGURE 3</label><caption><p>SQ reduced glomerular apoptotic podocytes in PHN rats. <bold>(A, B)</bold> C5b-9 assembly was visualized by immunofluorescence staining (magnification &#x000d7;1000) and semi-quantified using the ImageJ software. A Hoechst 33342 staining (magnification &#x000d7;400) revealed apoptotic podocytes. Data are presented as the mean &#x000b1; SD from independent groups. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. #<italic>p</italic> &#x0003c; 0.05 vs. the PHN group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g003" position="float"/></fig></sec><sec id="s4-5"><title>3.5 SQ reduced podocyte apoptosis by inhibiting EMT in PHN rats</title><p>EMT can cause highly differentiated podocytes to lose their epithelial phenotype and irreversible injury. Podocyte apoptosis is most likely the type of injury induced by cellular EMT. Increased Cleaved caspase-3, vimentin, and &#x003b1;-SMA expression, and decreased synaptopodin expression were observed in PHN rats. SQ-H and TAC significantly inhibited the upregulation of vimentin, &#x003b1;-SMA, and Cleaved caspase-3, and restored the downregulation of Synaptopodin in PHN rats (<xref rid="F4" ref-type="fig">Figures 4A&#x02013;G</xref>). These data revealed that SQ might inhibit podocyte apoptosis by inhibiting EMT in rats with PHN. It should be noted that increasing &#x003b2;-catenin expression in diabetes nephropathy can trigger mitochondrial-mediated apoptosis in podocytes by Bax/Bcl-2/caspase-3 pathway (<xref rid="B46" ref-type="bibr">Wang et al., 2018</xref>). Besides, we have previously demonstrated that SQ alleviates mitochondrial-mediated podocyte apoptosis in IMN via Bax/Bcl-2/caspase-3 pathway (<xref rid="B45" ref-type="bibr">Wang et al., 2021</xref>). Thus, we believe that SQ alleviated mitochondrial-mediated apoptosis in podocyte of IMN. Bax and Bcl-2 will not be checked repeatedly in this study.</p><fig position="float" id="F4"><label>FIGURE 4</label><caption><p>SQ reduced apoptotic podocytes by inhibiting EMT in PHN rats. <bold>(A&#x02013;C)</bold> Synaptopodin (magnification &#x000d7;1000) and Vimentin (magnification &#x000d7;1000) were visualized by immunofluorescence staining and semi-quantified using the ImageJ software. <bold>(D&#x02013;G)</bold> Protein levels of cleaved caspase-3, Caspase-3, vimentin, and &#x003b1;-SMA in the kidneys of all groups were detected by Western blotting. Data are presented as the mean &#x000b1; SD from independent groups. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g004" position="float"/></fig></sec><sec id="s4-6"><title>3.6 The ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway mediated the effects of SQ on EMT in PHN rats</title><p>Next, the protein expression levels of ERK, CK2-&#x003b1;, and &#x003b2;-catenin were determined. As shown in <xref rid="F5" ref-type="fig">Figures 5A&#x02013;E</xref>, ERK1/2, CK2-&#x003b1;, and &#x003b2;-catenin were implicated in the EMT process in PHN rats. The levels of p-ERK1/2, CK2-&#x003b1;, and &#x003b2;-catenin were strongly increased in PHN rats, whereas SQ-H treatment significantly reduced p-ERK1/2, CK2-&#x003b1;, and &#x003b2;-catenin protein levels. These data indicate that SQ may inhibit EMT in podocytes of PHN rats via the ERK/CK2-&#x003b1;/&#x003b2;-catenin signaling pathway <italic>in vivo</italic>.</p><fig position="float" id="F5"><label>FIGURE 5</label><caption><p>The ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway mediated the effects of SQ on EMT in PHN rats. <bold>(A&#x02013;E)</bold> Protein expression of p-ERK1, ERK1, p-ERK2, ERK2, CK2-&#x003b1;, and &#x003b2;-catenin was evaluated in the kidneys of all groups by Western blotting. Data are presented as the mean &#x000b1; SD from independent groups. *<italic>p</italic> &#x0003c; 0.05 vs. the CON group. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. #<italic>p</italic> &#x0003c; 0.05 vs. the PHN group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g005" position="float"/></fig></sec><sec id="s4-7"><title>3.7 SQ alleviated ADR-induced podocyte injury</title><p>We used an ADR-induced podocyte model to validate the protective effects of SQ against cell injury <italic>in vitro</italic> (<xref rid="F6" ref-type="fig">Figure 6A</xref>). Podocytes were treated with or without ADR/SQL, and cellular morphology, nucleus and cytoskeleton were examined (<xref rid="F6" ref-type="fig">Figures 6B&#x02013;D</xref>). ADR significantly reduced podocyte size and led to pseudopodia formation and podocyte detachment; SQL could migrate these changes. Moreover, ADR caused nuclear DNA fragmentation and a dramatic loss of cytoplasmic actin stress fibers in the cytoplasm of podocytes, which was partially recovered by SQL.</p><fig position="float" id="F6"><label>FIGURE 6</label><caption><p>SQ alleviated ADR-induced podocyte injury. <bold>(A)</bold> Diagram of the cell experiments. <bold>(B&#x02013;D)</bold> Morphological changes (magnification &#x000d7;100) in podocytes were recorded using a light microscope, the nuclear DNA fragmentation of the podocyte was visualized by TUNEL staining (magnification &#x000d7;200), and the podocyte cytoskeleton (magnification &#x000d7;400) was visualized by immunofluorescence staining. Semi-quantified using the ImageJ software. Data are presented as the mean &#x000b1; SD from independent groups. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g006" position="float"/></fig></sec><sec id="s4-8"><title>3.8 SQ reduced apoptosis in ADR-injured podocytes by suppressing EMT</title><p>In parallel with the animal experiments, ADR increased the levels of cleaved caspase-3, the mesenchymal proteins vimentin and &#x003b1;-SMA, and the epithelioid marker protein podocin in podocytes <italic>in vitro</italic> (<xref rid="F7" ref-type="fig">Figures 7A&#x02013;G</xref>). SQL reduced the protein changes (<xref rid="F7" ref-type="fig">Figures 7A&#x02013;G</xref>).</p><fig position="float" id="F7"><label>FIGURE 7</label><caption><p>SQ reduced apoptosis in ADR-injured podocytes by suppressing EMT. <bold>(A&#x02013;D)</bold> Cleaved caspase-3, Caspase-3, podocin, and vimentin protein levels in podocytes were measured by Western blotting. <bold>(E&#x02013;G)</bold> Vimentin (magnification &#x000d7;200) and &#x003b1;-SMA (magnification &#x000d7;200) in podocytes were visualized <bold>(E)</bold> by immunofluorescence staining and semi-quantified using ImageJ software. Data are presented as the mean &#x000b1; SD from independent groups. *<italic>p</italic> &#x0003c; 0.05 vs. the CON group. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. #<italic>p</italic> &#x0003c; 0.05 vs. the PHN group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g007" position="float"/></fig></sec><sec id="s4-9"><title>3.9 SQ inhibited ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway in ADR-injured podocytes</title><p>The EMT-pathway proteins ERK, CK2-&#x003b1;, and &#x003b2;-catenin were also measured in podocytes, with and without ADR/SQL intervention (<xref rid="F8" ref-type="fig">Figures 8A&#x02013;E</xref>). ADR significantly affected the protein expression levels of ERK, CK2-&#x003b1;, and &#x003b2;-catenin; however, SQL blocked these increases.</p><fig position="float" id="F8"><label>FIGURE 8</label><caption><p>SQ inhibited the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway in ADR-injured podocytes. <bold>(A&#x02013;E)</bold> Protein expression of p-ERK1, ERK1, p-ERK2, ERK2, CK2-&#x003b1;, and &#x003b2;-catenin in podocytes was measured by Western blotting. Data are presented as the mean &#x000b1; SD from independent groups. *<italic>p</italic> &#x0003c; 0.05 vs. the CON group. **<italic>p</italic> &#x0003c; 0.01 vs. the CON group. #<italic>p</italic> &#x0003c; 0.05 vs the PHN group. ##<italic>p</italic> &#x0003c; 0.01 vs. the PHN group.</p></caption><graphic xlink:href="fphar-16-1503961-g008" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s5"><title>4 Discussion</title><p>In the present study, SQ was shown to be absorbed by rats, reduced albuminuria, and relieved hyperlipidemia and podocyte loss in anti-Fx1A antiserum-challenged PHN rats in a dose-dependent manner. Apoptosis was induced in PHN rat kidneys and cultured podocytes and was alleviated by SQ treatment. Surprisingly, EMT is activated, resulting in glomerular injury, which is significantly reduced by SQ through the ERK/CK2-&#x003b1;/&#x003b2;-catenin signaling pathway. These data suggest that SQ exerts protective effects against podocyte apoptosis and renal pathological injury by inhibiting EMT through the ERK/CK2-&#x003b1;/&#x003b2;-catenin signaling pathway.</p><p>Apoptosis is considered a primary mode of cell death in diverse cell types (<xref rid="B42" ref-type="bibr">Tian et al., 2020</xref>; <xref rid="B34" ref-type="bibr">Newton et al., 2024</xref>; <xref rid="B33" ref-type="bibr">Moyer et al., 2025</xref>), and it is also the major cause of podocyte loss and albuminuria in IMN(<xref rid="B56" ref-type="bibr">Yin et al., 2021</xref>). It was previously demonstrated that oxidative stress (<xref rid="B8" ref-type="bibr">Gomaraschi et al., 2023</xref>), inflammation (<xref rid="B36" ref-type="bibr">Oh et al., 2023</xref>), and mitochondrial dysfunction (<xref rid="B54" ref-type="bibr">Yang et al., 2024</xref>), could induce apoptosis. However, the therapeutic strategies for oxidative stress, inflammation, and mitochondrial disorders do not completely inhibit apoptosis in podocytes. Therefore, there may be another mechanism that mediates podocyte apoptosis. EMT is a newly discovered type of podocyte injury (<xref rid="B25" ref-type="bibr">Li et al., 2023</xref>). EMT causes podocytes to transform from an epithelial phenotype to an interstitial phenotype, leading to irreversible cell injury (<xref rid="B23" ref-type="bibr">Li et al., 2022</xref>). Highly differentiated podocytes lose the support of key proteins during EMT, resulting in insufficient adhesion, apoptosis, and albuminuria. In the present study, SQ almost completely inhibited the occurrence of EMT in podocytes while mitigating apoptosis. These data indicate the widespread occurrence of EMT in the kidneys of PHN rats, and suggest that EMT inhibition may be a major factor underlying the pharmacological effects of SQ.</p><p>&#x003b2;-catenin is a multifunctional transcriptional regulatory protein (<xref rid="B3" ref-type="bibr">Dai et al., 2009</xref>). While &#x003b2;-catenin and &#x003b1;-catenin at the podocyte foot processes form a complex to maintain the tight adhesion between podocytes, &#x003b2;-catenin in the cytoplasm of podocytes is quickly degraded by GSK-3&#x003b2;-mediated phosphorylation. Elevated levels of &#x003b2;-catenin correlate with increased foot process fusion and the loss of foot process marker Nephrin in podocyte of human proteinuria nephropathy, and &#x003b2;-catenin knockout led to a significant reduction of podocyte damage and proteinuria (<xref rid="B3" ref-type="bibr">Dai et al., 2009</xref>; <xref rid="B2" ref-type="bibr">Chen et al., 2023</xref>). Besides, increasing &#x003b2;-catenin expression in diabetes nephropathy can trigger mitochondrial-mediated apoptosis in podocytes by Bax/Bcl-2/caspase-3 pathway (<xref rid="B46" ref-type="bibr">Wang et al., 2018</xref>). Thus, &#x003b2;-catenin is closely related to the occurrence of apoptosis in podocyte and proteinuria. Furthermore, it&#x02019;s confirmed that &#x003b2;-catenin is a key molecule that initiates podocyte EMT (<xref rid="B51" ref-type="bibr">Xiong et al., 2023</xref>). Inhibition of &#x003b2;-catenin, which is a highly conserved and ubiquitous serine and threonine protein kinase, effectively reduces EMT in apoptotic podocytes, and delays CKD (<xref rid="B18" ref-type="bibr">Kang et al., 2020</xref>). The increase of &#x003b2;-catenin in podocytes may be controlled by CK2-&#x003b1;. CK2-&#x003b1; is a highly pleiotropic protein kinase and closely related to various glomerular diseases (<xref rid="B22" ref-type="bibr">Li et al., 2024</xref>). CK2 is highly expressed in glomerulonephritis and renal biopsy specimens of patients with lupus nephritis, as well as in rat models of IgA nephropathy; and application of CK2 inhibitors can effectively control proteinuria and reduce podocyte apoptosis in rats with glomerulonephritis (<xref rid="B53" ref-type="bibr">Yamada et al., 2005</xref>). It has been confirmed that CK2-&#x003b1; can elevate &#x003b2;-catenin by inhibiting the phosphorylation of GSK-3&#x003b2;, but also release &#x003b2;-catenin by binding to &#x003b1;-catenin, resulting in an increase in free &#x003b2;-catenin in the cytoplasm (<xref rid="B38" ref-type="bibr">Seldin et al., 2005</xref>; <xref rid="B39" ref-type="bibr">Silva-Pavez and Tapia, 2020</xref>). More importantly, the activation of CK2-&#x003b1; is partially dependent on ERK. ERK is a serine and threonine protein kinase that belongs to the MAPK family (<xref rid="B28" ref-type="bibr">Liu J. et al., 2025</xref>). Activated ERK leads to acute and chronic renal disease (<xref rid="B17" ref-type="bibr">Jung et al., 2020</xref>; <xref rid="B30" ref-type="bibr">Livingston et al., 2024</xref>). An aberrant effect of ERK was also confirmed in proteinuric glomerular diseases, such as diabetic nephropathy, glomerulosclerosis, and nephritic syndrome (<xref rid="B6" ref-type="bibr">Das et al., 2019</xref>; <xref rid="B37" ref-type="bibr">Pan et al., 2025</xref>; <xref rid="B60" ref-type="bibr">Zhang et al., 2025</xref>). Moreover, it has been demonstrated that ERK has a key role in regulating EMT in renal tubular epithelial cells (<xref rid="B16" ref-type="bibr">Juan et al., 2023</xref>). Researcher has demonstrated that activated ERK can mutate S360/S362A residues to enhance CK2-&#x003b1; activity (<xref rid="B12" ref-type="bibr">Ji et al., 2009</xref>). The present study indicated that ERK/CK2-&#x003b1;/&#x003b2;-catenin signaling pathway is involved in podocyte EMT, and SQ alleviates EMT-mediated podocyte apoptosis via the ERK/CK2-&#x003b1;/&#x003b2;-catenin pathway.</p><p>Actually,the major components of SQ have also been reported to target EMT-related molecules. Calycosin can target ERK-mediated apoptosis in H9c2 cells to reduce heat shock, but also directly regulate cell EMT to treat colorectal cancer (<xref rid="B44" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="B20" ref-type="bibr">Lai et al., 2024</xref>). Moreover, caylcosin-7-O-&#x003b2;-D-glucopyranoside promotes osteoblast differentiation by modulating &#x003b2;-catenin (<xref rid="B13" ref-type="bibr">Jian et al., 2015</xref>). Notoginsenoside R1 can reduce heart damage caused by high altitude hypoxia in rats by activating ERK1/2, in addition to increase Lgr5<sup>+</sup> stem cell and epithelial healing in colitis mice by stimulating Wnt/&#x003b2;-Catenin signaling (<xref rid="B62" ref-type="bibr">Zhao et al., 2023</xref>; <xref rid="B57" ref-type="bibr">Yu et al., 2024</xref>). Ginsenoside Re inhibits melanoma development by downregulating ERK and reduces EMT in non-small cell lung cancer cells by interfering with M2-like macrophage polarization (<xref rid="B11" ref-type="bibr">Hwang et al., 2023</xref>; <xref rid="B41" ref-type="bibr">Tang et al., 2024</xref>). Ginsenoside Rg1 regulates cell apoptosis and improves Alzheimer&#x02019;s disease via the Wnt/GSK-3&#x003b2;/&#x003b2;-catenin signaling pathway (<xref rid="B55" ref-type="bibr">Yang et al., 2022</xref>). Ginsenoside Rb1 inhibits porcine epidemic diarrhea virus replication by suppressing the MAPK/ERK pathway and reducing cell apoptosis, and improves Bavachin induced renal fibrosis by inhibiting EMT (<xref rid="B35" ref-type="bibr">Ni et al., 2022</xref>; <xref rid="B64" ref-type="bibr">Zheng X. et al., 2025</xref>). Ginsenoside Rd promotes Differentiation of Myeloid Leukemia Cells via modulating the ERK/GSK-3&#x003b2; signaling pathway (<xref rid="B15" ref-type="bibr">Jiang et al., 2024</xref>). Ononin prevents angiogenesis by inhibiting the MEK/Erk signaling pathway (<xref rid="B9" ref-type="bibr">Gong et al., 2021</xref>). The research outcomes presented above support our findings.</p><p>This study elucidated EMT activation in apoptotic podocytes of IMN and the role of SQ in EMT activation, as well as performed a correlation analysis on the signaling pathways that mediate EMT activation utilizing previously published studies. However, the mechanisms underlying EMT and the role of SQ in it have not been thoroughly investigated. Specially, &#x003b2;-catenin is a crucial molecule for EMT activation in podocytes and also a vital molecule for tight adhesion of podocyte processes. The likely mechanism of higher &#x003b2;-catenin protein levels in podocytes in IMN is still unknown. All of these subjects should be investigated further in subsequent research.</p></sec><sec sec-type="conclusion" id="s6"><title>5 Conclusion</title><p>In the present study, we identified SQ as a potential candidate for renoprotective effects in PHN rats by inhibiting podocyte apoptosis by reducing podocyte EMT. Moreover, SQ had an eliminative effect on podocyte EMT via the ERK/CK2-&#x003b1;/&#x003b2;-catenin signaling pathway. These data confirm that SQ is a promising therapeutic traditional Chinese medicine for IMN treatment.</p></sec></body><back><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s13" ref-type="sec">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="s8"><title>Ethics statement</title><p>The animal study was approved by Animal Care and Use Committee of Guangdong Provincial Hospital of Chinese Medicine. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="s9"><title>Author contributions</title><p>XW: Data curation, Investigation, Visualization, Writing &#x02013; original draft. JW: Data curation, Validation, Writing &#x02013; review and editing. BZ: Formal Analysis, Resources, Writing &#x02013; review and editing. RT: Methodology, Software, Writing &#x02013; review and editing. LH: Methodology, Validation, Writing &#x02013; review and editing. WM: Supervision, Writing &#x02013; review and editing. YF: Methodology, Resources, Writing &#x02013; review and editing. BL: Conceptualization, Project administration, Supervision, Writing &#x02013; review and editing. PX: Conceptualization, Project administration, Supervision, Writing &#x02013; review and editing.</p></sec><sec sec-type="COI-statement" id="s11"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s12"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s13"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s14"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1503961/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fphar.2025.1503961/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="DataSheet1.zip"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data"><media xlink:href="DataSheet3.pdf"/></supplementary-material><supplementary-material id="SM3" position="float" content-type="local-data"><media xlink:href="DataSheet2.zip"/></supplementary-material><supplementary-material id="SM4" position="float" content-type="local-data"><media xlink:href="Supplementaryfile1.doc"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cai</surname><given-names>A.</given-names></name><name><surname>Meng</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Shao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Podocyte pathogenic bone morphogenetic protein-2 pathway and immune cell behaviors in primary membranous nephropathy</article-title>. <source>Adv. Sci. Weinheim, Baden-Wurttemberg, Ger.</source>
<volume>11</volume>, <fpage>e2404151</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202404151</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>S. M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Jia</surname><given-names>X. Y.</given-names></name><name><surname>Xuan</surname><given-names>Z. H.</given-names></name><name><surname>Cheng</surname><given-names>Z. L.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Wnt/&#x003b2;-catenin signaling pathway promotes abnormal activation of fibroblast-like synoviocytes and angiogenesis in rheumatoid arthritis and the intervention of Er Miao San</article-title>. <source>Phytomedicine</source>
<volume>120</volume>, <fpage>155064</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2023.155064</pub-id>
<pub-id pub-id-type="pmid">37716035</pub-id>
</mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>C. S.</given-names></name><name><surname>Stolz</surname><given-names>D. B.</given-names></name><name><surname>Kiss</surname><given-names>L. P.</given-names></name><name><surname>Monga</surname><given-names>S. P.</given-names></name><name><surname>Holzman</surname><given-names>L. B.</given-names></name><name><surname>Liu</surname><given-names>Y. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria</article-title>. <source>J. Am. Soc. Nephrol.</source>
<volume>20</volume> (<issue>9</issue>), <fpage>1997</fpage>&#x02013;<lpage>2008</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2009010019</pub-id>
<pub-id pub-id-type="pmid">19628668</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dai</surname><given-names>X. G.</given-names></name><name><surname>Feng</surname><given-names>J. X.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Syndrome differentiation and treatment of chronic kidney disease treated with traditional Chinese medicine</article-title>. <source>Chin. J. Integr. Tradit. West. Nephrol.</source>
<volume>14</volume> (<issue>10</issue>), <fpage>933</fpage>&#x02013;<lpage>934</lpage>.</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dan Hu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>H.-L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Tan</surname><given-names>R.-Z.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Btg2 promotes focal segmental glomerulosclerosis via smad3-dependent podocyte-mesenchymal transition</article-title>. <source>Adv. Sci. Weinheim, Baden-Wurttemberg, Ger.</source>
<volume>10</volume> (<issue>32</issue>), <fpage>e2304360</fpage>. <pub-id pub-id-type="doi">10.1002/advs.202304360</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>S. J.</given-names></name><name><surname>Nguyen</surname><given-names>N. T.</given-names></name><name><surname>Kwon</surname><given-names>H. J.</given-names></name><name><surname>Cha</surname><given-names>S. K.</given-names></name><name><surname>Park</surname><given-names>K. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-&#x003b2; in Adriamycin-induced glomerulosclerosis</article-title>. <source>Kidney Int.</source>
<volume>96</volume> (<issue>4</issue>), <fpage>927</fpage>&#x02013;<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2019.05.006</pub-id>
<pub-id pub-id-type="pmid">31377057</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Ju&#x000e1;rez</surname><given-names>G.</given-names></name><name><surname>Rojas-Rivera</surname><given-names>J.</given-names></name><name><surname>Logt</surname><given-names>A.-E. v.d.</given-names></name><name><surname>Justino</surname><given-names>J.</given-names></name><name><surname>Sevillano</surname><given-names>A.</given-names></name><name><surname>Caravaca-Font&#x000e1;n</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy</article-title>. <source>Kidney Int.</source>
<volume>99</volume> (<issue>4</issue>), <fpage>986</fpage>&#x02013;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2020.10.014</pub-id>
<pub-id pub-id-type="pmid">33166580</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomaraschi</surname><given-names>M.</given-names></name><name><surname>Turri</surname><given-names>M.</given-names></name><name><surname>Strazzella</surname><given-names>A.</given-names></name><name><surname>Lhomme</surname><given-names>M.</given-names></name><name><surname>Pavanello</surname><given-names>C.</given-names></name><name><surname>Le Goff</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Abnormal lipoproteins trigger oxidative stress-mediated apoptosis of renal cells in LCAT deficiency</article-title>. <source>Antioxidants (Basel)</source>
<volume>12</volume> (<issue>8</issue>), <fpage>1498</fpage>. <pub-id pub-id-type="doi">10.3390/antiox12081498</pub-id>
<pub-id pub-id-type="pmid">37627492</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Anti-angiogenesis function of ononin via suppressing the MEK/erk signaling pathway</article-title>. <source>J. Nat. Prod.</source>
<volume>84</volume> (<issue>6</issue>), <fpage>1755</fpage>&#x02013;<lpage>1762</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jnatprod.1c00008</pub-id>
<pub-id pub-id-type="pmid">34029083</pub-id>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Liao</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Zinc deficiency causes glomerulosclerosis and renal interstitial fibrosis through oxidative stress and increased lactate metabolism in rats</article-title>. <source>Biol. Trace Elem. Res.</source>
<volume>203</volume> (<issue>4</issue>), <fpage>2084</fpage>&#x02013;<lpage>2098</lpage>. <pub-id pub-id-type="doi">10.1007/s12011-024-04306-1</pub-id>
<pub-id pub-id-type="pmid">39028478</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hwang</surname><given-names>S. J.</given-names></name><name><surname>Bang</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>H.-J.</given-names></name></person-group> (<year>2023</year>). <article-title>Ginsenosi<italic>de re</italic> inhibits melanogenesis and melanoma growth by downregulating microphthalmia-associated transcription factor</article-title>. <source>Biomed. and Pharmacother. = Biomedecine and Pharmacother.</source>
<volume>165</volume>, <fpage>115037</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.115037</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ji</surname><given-names>H. T.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Nika</surname><given-names>H.</given-names></name><name><surname>Hawke</surname><given-names>D.</given-names></name><name><surname>Keezer</surname><given-names>S.</given-names></name><name><surname>Ge</surname><given-names>Q. Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>EGF-induced ERK activation promotes CK2-mediated disassociation of &#x003b1;-catenin from &#x003b2;-catenin and transactivation of &#x003b2;-catenin</article-title>. <source>Mol. Cell</source>
<volume>36</volume> (<issue>4</issue>), <fpage>547</fpage>&#x02013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2009.09.034</pub-id>
<pub-id pub-id-type="pmid">19941816</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jian</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Calycosin-7-O-&#x003b2;-d-glucopyranoside stimulates osteoblast differentiation through regulating the BMP/WNT signaling pathways</article-title>. <source>Acta Pharm. Sin.</source>
<volume>5</volume> (<issue>5</issue>), <fpage>454</fpage>&#x02013;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2015.06.005</pub-id>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Zhuang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy</article-title>. <source>Front. Immunol.</source>
<volume>14</volume>, <fpage>1335936</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1335936</pub-id>
<pub-id pub-id-type="pmid">38288116</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.-X.</given-names></name><name><surname>Zhao</surname><given-names>Y.-N.</given-names></name><name><surname>Yu</surname><given-names>X.-L.</given-names></name><name><surname>Yin</surname><given-names>L.-M.</given-names></name></person-group> (<year>2024</year>). <article-title>Ginsenoside Rd induces differentiation of myeloid leukemia cells via regulating ERK/GSK-3&#x003b2; signaling pathway</article-title>. <source>Chin. J. Integr. Med.</source>
<volume>30</volume> (<issue>7</issue>), <fpage>588</fpage>&#x02013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-023-3561-z</pub-id>
<pub-id pub-id-type="pmid">38085388</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Juan</surname><given-names>Y.-H.</given-names></name><name><surname>Yu</surname><given-names>Y.-L.</given-names></name><name><surname>Tsai</surname><given-names>Y.-P.</given-names></name><name><surname>Lee</surname><given-names>C.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-S.</given-names></name><name><surname>Ting</surname><given-names>Y.-H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Alpha-mangostin alleviate renal interstitial fibrosis via suppression of TGF-&#x003b2;1/Smad/ERK signaling axis <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>Biochem. Pharmacol.</source>
<volume>218</volume>, <fpage>115935</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2023.115935</pub-id>
<pub-id pub-id-type="pmid">37989414</pub-id>
</mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jung</surname><given-names>H. Y.</given-names></name><name><surname>Oh</surname><given-names>S. H.</given-names></name><name><surname>Ahn</surname><given-names>J. S.</given-names></name><name><surname>Oh</surname><given-names>E. J.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Kim</surname><given-names>C. D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>NOX1 inhibition attenuates kidney ischemia-reperfusion injury via inhibition of ROS-mediated ERK signaling</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume> (<issue>18</issue>), <fpage>6911</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21186911</pub-id>
<pub-id pub-id-type="pmid">32967113</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>M. K.</given-names></name><name><surname>Kim</surname><given-names>S. I.</given-names></name><name><surname>Oh</surname><given-names>S. Y.</given-names></name><name><surname>Na</surname><given-names>W.</given-names></name><name><surname>Kang</surname><given-names>Y. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Tangeretin ameliorates glucose-induced podocyte injury through blocking epithelial to mesenchymal transition caused by oxidative stress and hypoxia</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume> (<issue>22</issue>), <fpage>8577</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21228577</pub-id>
<pub-id pub-id-type="pmid">33202982</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kistler</surname><given-names>A. D.</given-names></name><name><surname>Salant</surname><given-names>D. J.</given-names></name></person-group> (<year>2024</year>). <article-title>Complement activation and effector pathways in membranous nephropathy</article-title>. <source>Kidney Int.</source>
<volume>105</volume> (<issue>3</issue>), <fpage>473</fpage>&#x02013;<lpage>483</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2023.10.035</pub-id>
<pub-id pub-id-type="pmid">38142037</pub-id>
</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>P.-F.</given-names></name><name><surname>Mahendran</surname><given-names>R.</given-names></name><name><surname>Tsai</surname><given-names>B.C.-K.</given-names></name><name><surname>Lu</surname><given-names>C.-Y.</given-names></name><name><surname>Kuo</surname><given-names>C.-H.</given-names></name><name><surname>Lin</surname><given-names>K.-H.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Calycosin enhances heat shock related-proteins in H9c2 cells to modulate survival and apoptosis against heat shock</article-title>. <source>Am. J. Chin. Med.</source>
<volume>52</volume> (<issue>4</issue>), <fpage>1173</fpage>&#x02013;<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.1142/S0192415X24500472</pub-id>
<pub-id pub-id-type="pmid">38938156</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>B.</given-names></name><name><surname>Yu</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Research progress in the treatment of idiopathic membranous nephropathy using traditional Chinese medicine</article-title>. <source>J. Transl. Int. Med.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>3</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2478/jtim-2020-0002</pub-id>
<pub-id pub-id-type="pmid">32435606</pub-id>
</mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Multiple roles of mitochondrial autophagy receptor FUNDC1 in mitochondrial events and kidney disease</article-title>. <source>Front. Cell Dev. Biol.</source>
<volume>12</volume>, <fpage>1453365</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2024.1453365</pub-id>
<pub-id pub-id-type="pmid">39445333</pub-id>
</mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Microtubule associated protein 4 phosphorylation-induced epithelial-to-mesenchymal transition of podocyte leads to proteinuria in diabetic nephropathy</article-title>. <source>Cell Commun. Signal. CCS</source>
<volume>20</volume> (<issue>1</issue>), <fpage>115</fpage>. <pub-id pub-id-type="doi">10.1186/s12964-022-00883-7</pub-id>
<pub-id pub-id-type="pmid">35902952</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Tong</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Targeting the NF-&#x003ba;B p65-MMP28 axis: wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy</article-title>. <source>Phytomedicine Int. J. Phytotherapy Phytopharm.</source>
<volume>138</volume>, <fpage>156406</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2025.156406</pub-id>
</mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X.-Y.</given-names></name><name><surname>Chen</surname><given-names>H.-R.</given-names></name><name><surname>Kuang</surname><given-names>D.-D.</given-names></name><name><surname>Pan</surname><given-names>L.-H.</given-names></name><name><surname>Li</surname><given-names>Q.-M.</given-names></name><name><surname>Luo</surname><given-names>J.-P.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Laminaria japonica polysaccharide attenuates podocyte epithelial-mesenchymal transformation via TGF-&#x003b2;1-mediated Smad3 and p38MAPK pathways</article-title>. <source>Int. J. Biol. Macromol.</source>
<volume>241</volume>, <fpage>124637</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.124637</pub-id>
<pub-id pub-id-type="pmid">37121417</pub-id>
</mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Lei</surname><given-names>X. Q.</given-names></name><name><surname>Yang</surname><given-names>J. K.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Tan</surname><given-names>R. Z.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Astragalus mongholicus Bunge and Panax notoginseng formula (A&#x00026;P) improves renal mesangial cell damage in diabetic nephropathy by inhibiting the inflammatory response of infiltrated macrophages</article-title>. <source>BMC Complement. Med. Ther.</source>
<volume>22</volume> (<issue>1</issue>), <fpage>17</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-021-03477-x</pub-id>
<pub-id pub-id-type="pmid">35057768</pub-id>
</mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Crocin improves the renal autophagy in rat experimental membranous nephropathy via regulating the SIRT1/Nrf2/HO-1 signaling pathway</article-title>. <source>Ren. Fail.</source>
<volume>45</volume> (<issue>2</issue>), <fpage>2253924</fpage>. <pub-id pub-id-type="doi">10.1080/0886022X.2023.2253924</pub-id>
<pub-id pub-id-type="pmid">37724538</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zuo</surname><given-names>Z.</given-names></name><name><surname>Ewing</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2025a</year>). <article-title>ERK pathway reactivation prevents anthrax toxin lethality in mice</article-title>. <source>Nat. Microbiol</source>. <pub-id pub-id-type="doi">10.1038/s41564-025-01977-x</pub-id>
</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name></person-group> (<year>2025b</year>). <article-title>Complement-coagulation crosstalk in idiopathic membranous nephropathy: the potential pathogenesis and therapeutic perspective</article-title>. <source>Autoimmun. Rev.</source>
<volume>24</volume> (<issue>5</issue>), <fpage>103763</fpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2025.103763</pub-id>
<pub-id pub-id-type="pmid">39914678</pub-id>
</mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Livingston</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Kwon</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Manicassamy</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Autophagy activates EGR1 via MAPK/ERK to induce FGF2 in renal tubular cells for fibroblast activation and fibrosis during maladaptive kidney repair</article-title>. <source>Autophagy</source>
<volume>20</volume> (<issue>5</issue>), <fpage>1032</fpage>&#x02013;<lpage>1053</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2023.2281156</pub-id>
<pub-id pub-id-type="pmid">37978868</pub-id>
</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Membranous nephropathy: systems biology-based novel mechanism and traditional Chinese medicine therapy</article-title>. <source>Front. Pharmacol.</source>
<volume>13</volume>, <fpage>969930</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.969930</pub-id>
<pub-id pub-id-type="pmid">36176440</pub-id>
</mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morelle</surname><given-names>J.</given-names></name><name><surname>Aydin</surname><given-names>S.</given-names></name><name><surname>Debiec</surname><given-names>H.</given-names></name><name><surname>Demoulin</surname><given-names>N.</given-names></name><name><surname>Dufour</surname><given-names>I.</given-names></name><name><surname>Martin</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Mass spectrometry with data-independent acquisition for the identification of target antigens in membranous nephropathy</article-title>. <source>Am. J. Kidney Dis. Official J. Natl. Kidney Found</source>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2025.01.014</pub-id>
</mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moyer</surname><given-names>A.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Cheng</surname><given-names>E. H.</given-names></name></person-group> (<year>2025</year>). <article-title>Apoptosis in cancer biology and therapy</article-title>. <source>Annu. Rev. Pathology</source>
<volume>20</volume> (<issue>1</issue>), <fpage>303</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-051222-115023</pub-id>
</mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newton</surname><given-names>K.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name><name><surname>Kayagaki</surname><given-names>N.</given-names></name><name><surname>Dixit</surname><given-names>V. M.</given-names></name></person-group> (<year>2024</year>). <article-title>Cell death</article-title>. <source>Cell</source>
<volume>187</volume> (<issue>2</issue>), <fpage>235</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.11.044</pub-id>
<pub-id pub-id-type="pmid">38242081</pub-id>
</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y.-H.</given-names></name><name><surname>Deng</surname><given-names>H.-F.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>C.-S.</given-names></name><name><surname>Wang</surname><given-names>N.-N.</given-names></name><name><surname>Yue</surname><given-names>L.-X.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Ginsenoside Rb1 ameliorated bavachin-induced renal fibrosis via suppressing bip/eIF2&#x003b1;/CHOP signaling-mediated EMT</article-title>. <source>Front. Pharmacol.</source>
<volume>13</volume>, <fpage>872474</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.872474</pub-id>
<pub-id pub-id-type="pmid">35873571</pub-id>
</mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oh</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>W.</given-names></name><name><surname>Park</surname><given-names>S. Y.</given-names></name><name><surname>Abd El-Aty</surname><given-names>A. M.</given-names></name><name><surname>Jeong</surname><given-names>J. H.</given-names></name><name><surname>Jung</surname><given-names>T. W.</given-names></name></person-group> (<year>2023</year>). <article-title>Ginsenoside Rb3 ameliorates podocyte injury under hyperlipidemic conditions via PPAR&#x003b4;- or SIRT6-mediated suppression of inflammation and oxidative stress</article-title>. <source>J. Ginseng Res.</source>
<volume>47</volume> (<issue>3</issue>), <fpage>400</fpage>&#x02013;<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1016/j.jgr.2022.11.006</pub-id>
<pub-id pub-id-type="pmid">37252277</pub-id>
</mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>D.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Oleanolic acid inhibits mesangial cell proliferation and inflammatory response in mesangial proliferative glomerulonephritis through IL-17/ERK/AKT pathway</article-title>. <source>Int. Immunopharmacol.</source>
<volume>152</volume>, <fpage>114459</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2025.114459</pub-id>
<pub-id pub-id-type="pmid">40088868</pub-id>
</mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seldin</surname><given-names>D. C.</given-names></name><name><surname>Landesman-Bollag</surname><given-names>E.</given-names></name><name><surname>Farago</surname><given-names>M.</given-names></name><name><surname>Currier</surname><given-names>N.</given-names></name><name><surname>Lou</surname><given-names>D.</given-names></name><name><surname>Dominguez</surname><given-names>I.</given-names></name></person-group> (<year>2005</year>). <article-title>CK2 as a positive regulator of Wnt signalling and tumourigenesis</article-title>. <source>Mol. Cell Biochem.</source>
<volume>274</volume> (<issue>1-2</issue>), <fpage>63</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-005-3078-0</pub-id>
<pub-id pub-id-type="pmid">16342409</pub-id>
</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silva-Pavez</surname><given-names>E.</given-names></name><name><surname>Tapia</surname><given-names>J. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Protein kinase CK2 in cancer energetics</article-title>. <source>Front. Oncol.</source>
<volume>10</volume>, <fpage>893</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.00893</pub-id>
<pub-id pub-id-type="pmid">32626654</pub-id>
</mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>R. Z.</given-names></name><name><surname>Diao</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J. C.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X. J.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Astragalus mongholicus Bunge and Panax notoginseng formula (A&#x00026;P) combined with bifidobacterium contribute a renoprotective effect in chronic kidney disease through inhibiting macrophage inflammatory response in kidney and intestine</article-title>. <source>Front. Physiol.</source>
<volume>11</volume>, <fpage>583668</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2020.583668</pub-id>
<pub-id pub-id-type="pmid">33329031</pub-id>
</mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Ginsenosi<italic>de re</italic> inhibits non-small cell lung cancer progression by suppressing macrophage M2 polarization induced by AMPK&#x003b1;1/STING positive feedback loop</article-title>. <source>Phytotherapy Res. PTR</source>
<volume>38</volume> (<issue>11</issue>), <fpage>5088</fpage>&#x02013;<lpage>5106</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.8309</pub-id>
</mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>You</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Apoptosis exerts a vital role in the treatment of colitis-associated cancer by herbal medicine</article-title>. <source>Front. Pharmacol.</source>
<volume>11</volume>, <fpage>438</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00438</pub-id>
<pub-id pub-id-type="pmid">32410986</pub-id>
</mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Shang</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Tian</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Myostatin silencing inhibits podocyte apoptosis in membranous nephropathy through Smad3/PKA/NOX4 signaling pathway</article-title>. <source>Open Med. Wars. Pol.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>20220615</fpage>. <pub-id pub-id-type="doi">10.1515/med-2022-0615</pub-id>
</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>W.</given-names></name><name><surname>Yin</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name></person-group> (<year>2019</year>). <article-title>Calycosin suppresses TGF-&#x003b2;-induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells</article-title>. <source>J. Exp. and Clin. Cancer Res. CR</source>
<volume>38</volume> (<issue>1</issue>), <fpage>240</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-019-1243-7</pub-id>
<pub-id pub-id-type="pmid">31174572</pub-id>
</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X. W.</given-names></name><name><surname>Liu</surname><given-names>J. C.</given-names></name><name><surname>Tian</surname><given-names>R. M.</given-names></name><name><surname>Zheng</surname><given-names>B. D.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>L. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Sanqi oral solution mitigates proteinuria in rat passive Heymann nephritis and blocks podocyte apoptosis via Nrf2/HO-1 pathway</article-title>. <source>Front. Pharmacol.</source>
<volume>12</volume>, <fpage>727874</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.727874</pub-id>
<pub-id pub-id-type="pmid">34867334</pub-id>
</mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>S.-P.</given-names></name></person-group> (<year>2018</year>). <article-title>&#x003b2;-Arrestin 1/2 aggravates podocyte apoptosis of diabetic nephropathy via wnt/&#x003b2;-catenin pathway</article-title>. <source>Med. Sci. Monit.</source>
<volume>24</volume>, <fpage>1724</fpage>&#x02013;<lpage>1732</lpage>. <pub-id pub-id-type="doi">10.12659/msm.905642</pub-id>
<pub-id pub-id-type="pmid">29572435</pub-id>
</mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Fangji Huangqi decoction ameliorates membranous nephropathy through the upregulation of BNIP3-mediated mitophagy</article-title>. <source>J. Ethnopharmacol.</source>
<volume>324</volume>, <fpage>117734</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2024.117734</pub-id>
<pub-id pub-id-type="pmid">38237645</pub-id>
</mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>M.</given-names></name><name><surname>Sheng</surname><given-names>L.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Shen-Qi-Di-Huang Decoction induces autophagy in podocytes to ameliorate membranous nephropathy by suppressing USP14</article-title>. <source>J. Ethnopharmacol.</source>
<volume>340</volume>, <fpage>119228</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2024.119228</pub-id>
<pub-id pub-id-type="pmid">39647591</pub-id>
</mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>F. N.</given-names></name><name><surname>Chen</surname><given-names>Z. L.</given-names></name><name><surname>Yang</surname><given-names>H. F.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>H. M.</given-names></name><name><surname>Deng</surname><given-names>S. G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Effect of Sanqi Oral Liquid on the expressions of CD4<sup>+</sup>, CD8<sup>+</sup> and CD68<sup>+</sup> cells in 5/6 nephrectomized rats with chronic renal failure</article-title>. <source>Chin. J. Integr. Med.</source>
<volume>19</volume> (<issue>8</issue>), <fpage>589</fpage>&#x02013;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1007/s11655-012-1233-5</pub-id>
<pub-id pub-id-type="pmid">23212567</pub-id>
</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Tan</surname><given-names>R. Z.</given-names></name><name><surname>Zhao</surname><given-names>C. Y.</given-names></name><name><surname>Li</surname><given-names>J. C.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Diao</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Astragalus mongholicus Bunge and Panax notoginseng (burkill) F.H. Chen formula for renal injury in diabetic nephropathy-<italic>in vivo</italic> and <italic>in vitro</italic> evidence for autophagy regulation</article-title>. <source>Front. Pharmacol.</source>
<volume>12</volume> (<issue>11</issue>), <fpage>732</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.00732</pub-id>
</mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Rhein inhibited ferroptosis and EMT to attenuate diabetic nephropathy by regulating the rac1/NOX1/&#x003b2;-catenin Axis</article-title>. <source>Front. Biosci. Landmark Ed.</source>
<volume>28</volume> (<issue>5</issue>), <fpage>100</fpage>. <pub-id pub-id-type="doi">10.31083/j.fbl2805100</pub-id>
<pub-id pub-id-type="pmid">37258467</pub-id>
</mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>S. H.</given-names></name><name><surname>Tian</surname><given-names>R. M.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Mao</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Metabonomic analysis of the therapeutic effects of Chinese medicine Sanqi oral solution on rats with exhaustive exercise</article-title>. <source>Front. Pharmacol.</source>
<volume>10</volume>, <fpage>00704</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.00704</pub-id>
</mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Katsuma</surname><given-names>S.</given-names></name><name><surname>Adachi</surname><given-names>T.</given-names></name><name><surname>Hirasawa</surname><given-names>A.</given-names></name><name><surname>Shiojima</surname><given-names>S.</given-names></name><name><surname>Kadowaki</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<volume>102</volume> (<issue>21</issue>), <fpage>7736</fpage>&#x02013;<lpage>7741</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0409818102</pub-id>
<pub-id pub-id-type="pmid">15897466</pub-id>
</mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Tao</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Scutellarin ameliorates mitochondrial dysfunction and apoptosis in OGD/R-insulted HT22 cells through mitophagy induction</article-title>. <source>Biomed. and Pharmacother. = Biomedecine and Pharmacother.</source>
<volume>179</volume>, <fpage>117340</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.117340</pub-id>
</mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3&#x003b2;/&#x003b2;-catenin signaling pathway</article-title>. <source>Chem. Biol. and Drug Des.</source>
<volume>99</volume> (<issue>6</issue>), <fpage>884</fpage>&#x02013;<lpage>896</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.14041</pub-id>
<pub-id pub-id-type="pmid">35313087</pub-id>
</mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Controversies in podocyte loss: death or detachment?</article-title>
<source>Front. Cell Dev. Biol.</source>
<volume>9</volume>, <fpage>771931</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.771931</pub-id>
<pub-id pub-id-type="pmid">34881244</pub-id>
</mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z.-L.</given-names></name><name><surname>Gao</surname><given-names>R.-Y.</given-names></name><name><surname>Lv</surname><given-names>C.</given-names></name><name><surname>Geng</surname><given-names>X.-L.</given-names></name><name><surname>Ren</surname><given-names>Y.-J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Notoginsenoside R1 promotes Lgr5+ stem cell and epithelium renovation in colitis mice via activating Wnt/&#x003b2;-Catenin signaling</article-title>. <source>Acta Pharmacol. Sin.</source>
<volume>45</volume> (<issue>7</issue>), <fpage>1451</fpage>&#x02013;<lpage>1465</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-024-01250-7</pub-id>
<pub-id pub-id-type="pmid">38491161</pub-id>
</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yue</surname><given-names>J. I.</given-names></name><name><surname>Xin-Yuan</surname><given-names>Z. H. A. N. G.</given-names></name><name><surname>Yun-Ming</surname><given-names>X. I. A. O.</given-names></name><name><surname>Zi-Hao</surname><given-names>Z. H. U. A. N. G.</given-names></name><name><surname>Xiao-Hui</surname><given-names>Y. A. N. G.</given-names></name><name><surname>Xin-Ju</surname><given-names>L. I.</given-names></name></person-group> (<year>2024</year>). <article-title>Acupuncture improve proteinuria in diabetic kidney disease rats by inhibiting ferroptosis and epithelial-mesenchymal transition</article-title>. <source>Heliyon</source>
<volume>10</volume> (<issue>13</issue>), <fpage>e33675</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e33675</pub-id>
<pub-id pub-id-type="pmid">39071725</pub-id>
</mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Bin</surname><given-names>S.</given-names></name><name><surname>Budge</surname><given-names>K.</given-names></name><name><surname>Petrosyan</surname><given-names>A.</given-names></name><name><surname>Villani</surname><given-names>V.</given-names></name><name><surname>Aguiari</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy</article-title>. <source>JCI Insight</source>
<volume>9</volume> (<issue>4</issue>), <fpage>e172976</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.172976</pub-id>
<pub-id pub-id-type="pmid">38227377</pub-id>
</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>D.</given-names></name><name><surname>Niu</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Kidney gastrin/CCKBR attenuates type 2 diabetes mellitus by inhibiting SGLT2-mediated glucose reabsorption through erk/NF-&#x003ba;B signaling pathway</article-title>. <source>Diabetes and Metabolism J.</source>
<volume>49</volume> (<issue>2</issue>), <fpage>194</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.4093/dmj.2023.0397</pub-id>
</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Hou</surname><given-names>F.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Activation of the IL-6/STAT3 pathway contributes to the pathogenesis of membranous nephropathy and is a target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to repair podocyte damage</article-title>. <source>Biomed. and Pharmacother. = Biomedecine and Pharmacother.</source>
<volume>174</volume>, <fpage>116583</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2024.116583</pub-id>
</mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>N.</given-names></name><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Pei</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Pretreatment with Notoginsenoside R1 attenuates high-altitude hypoxia-induced cardiac injury via activation of the ERK1/2-P90RSK-Bad signaling pathway in rats</article-title>. <source>Phytotherapy Res. PTR</source>
<volume>37</volume> (<issue>10</issue>), <fpage>4522</fpage>&#x02013;<lpage>4539</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7923</pub-id>
</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>T.</given-names></name><name><surname>Gu</surname><given-names>Y.-P.</given-names></name><name><surname>Wang</surname><given-names>J.-M.</given-names></name><name><surname>Huang</surname><given-names>T.-T.</given-names></name><name><surname>Gou</surname><given-names>L.-S.</given-names></name><name><surname>Liu</surname><given-names>Y.-W.</given-names></name></person-group> (<year>2025a</year>). <article-title>Lactate-triggered histone lactylation contributes to podocyte epithelial-mesenchymal transition in diabetic nephropathy in mice</article-title>. <source>Chemico-biological Interact.</source>
<volume>408</volume>, <fpage>111418</fpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2025.111418</pub-id>
</mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Xiang</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name><name><surname>Kuang</surname><given-names>Q.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2025b</year>). <article-title>Ginsenoside Rb1 inhibits porcine epidemic diarrhea virus replication through suppressing S1 protein mediated the MAPK/ERK pathway and reducing apoptosis</article-title>. <source>Int. J. Biol. Macromol.</source>
<volume>304</volume> (<issue>Pt 2</issue>), <fpage>140937</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2025.140937</pub-id>
<pub-id pub-id-type="pmid">39947549</pub-id>
</mixed-citation></ref></ref-list></back></article>